Skip to main content

Advertisement

Table 2 Univariate analyses of overall survival in additional independent cases of BRCA, LIHC, LUAD, STAD, and ESCA

From: Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis

Cancer type Characteristic Total (cases) HR (95% CI) P
BRCA Age (years)
 ≤ 60 96 1.000  
 > 60 49 1.467 (0.864–2.752) 0.323
TNBCa
 No 109 1.000  
 Yes 24 2.296 (1.169–4.508) 0.016
TNM stageb
 I/II 95 1.000  
 III/IV 48 2.296 (1.279–4.120) 0.005
PGK1 pS203
 Low 65 1.000  
 High 80 1.905 (1.024–3.546) 0.042
PDHK1 pT338
 Low 66 1.000  
 High 79 1.969 (1.058–3.665) 0.032
LIHC Age (years)
 ≤ 60 75 1.000  
 > 60 110 1.351 (0.863–1.962) 0.527
Gender
 Male 159 1.000  
 Female 26 0.597 (0.327–1.087) 0.092
TNM stagec
 I/II 73 1.000  
 III/IV 104 2.796 (1.848–4.229) < 0.001
PGK1 pS203
 Low 107 1.000  
 High 78 1.909 (1.311–2.781) 0.001
PDHK1 pT338
 Low 105 1.000  
 High 80 2.354 (1.610–3.441) < 0.001
LUAD Age (years)
 ≤ 60 84 1.000  
 > 60 95 1.339 (0.944–1.900) 0.102
Gender
 Male 104 1.000  
 Female 75 0.775 (0.542–1.107) 0.162
TNM stage
 I/II 105 1.000  
 III/IV 74 1.861 (1.309–2.647) 0.001
PGK1 pS203
 Low 74 1.000  
 High 105 1.760 (1.221–2.537) 0.002
PDHK1 pT338
 Low 75 1.000  
 High 104 1.595 (1.111–2.291) 0.011
STAD Age (years)
 ≤ 60 56 1.000  
 > 60 39 1.754 (1.144–2.689) 0.010
Gender
 Male 60 1.000  
 Female 35 1.017 (0.660–1.567) 0.938
TNM staged
 I/II 24 1.000  
 III/IV 69 2.590 (1.536–4.365) < 0.001
PGK1 pS203
 Low 51 1.000  
 High 44 1.797 (1.173–2.752) 0.007
PDHK1 pT338
 Low 49 1.000  
 High 46 1.694 (1.105–2.596) 0.016
ESCA Age (years)
 ≤ 60 112 1.000  
 > 60 102 1.869 (1.300–2.686) 0.001
Gender
 Male 176 1.000  
 Female 38 1.127 (0.709–1.789) 0.614
TNM stage
 I/II 98 1.000  
 III/IV 116 6.447 (4.139–10.043) < 0.001
PGK1 pS203
 Low 103 1.000  
 High 111 1.669 (1.157–2.406) 0.006
PDHK1 pT338
 Low 94 1.000  
 High 120 1.763 (1.213–2.563) 0.003
  1. BRCA breast carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, STAD stomach adenocarcinoma, ESCA esophageal carcinoma, HR hazard ratio, 95% CI 95% confidence interval, TNBC triple-negative breast cancer, PGK1 pS203 phosphorylated phosphoglycerate kinase 1 (PGK1) S203, PDHK1 pT338 phosphorylated phosphorylate pyruvate dehydrogenase kinase 1 (PDHK1) T338
  2. aThe data of TNBC in BRCA were available in 133 patients
  3. bThe data of TNM stage in BRCA were available in 143 patients
  4. cThe data of TNM stage in LIHC were available in 177 patients
  5. dThe data of TNM stage in STAD were available in 93 patients